Publications
104 results found
Cooper N, 2017, State of the art - how I manage immune thrombocytopenia, British Journal of Haematology, Vol: 177, Pages: 39-54, ISSN: 0007-1048
Bussel JB, Cooper N, 2017, Immune thrombocytopenia: a need for assisted suicide, British Journal of Haematology, Vol: 176, Pages: 154-154, ISSN: 0007-1048
Grainger J, Bussel JB, Cooper N, et al., 2016, A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP), 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 4
Adams G, Graebner L, Sayed A, et al., 2016, Cytokine Fluctuations in Immune Thrombocytopenia (ITP) over Time; Insights into the Pathogenesis and Evolution of the Disease, 58th Annual Meeting and Exposition of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, ISSN: 0006-4971
Michel M, Wasser J, Godeau B, et al., 2015, Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥65 years with immune thrombocytopenia, Annals of Hematology, Vol: 94, Pages: 1973-1980, ISSN: 0939-5555
Cooper N, Bain BJ, 2015, Emperipolesis in a patient receiving romiplostim, American Journal of Hematology, Vol: 91, Pages: 166-166, ISSN: 1096-8652
Taylor A, Neave L, Solanki S, et al., 2015, Mycophenolate mofetil therapy for severe immune thrombocytopenia, British Journal of Haematology, Vol: 171, Pages: 625-630, ISSN: 0007-1048
<jats:title>Summary</jats:title><jats:p>Severe immune thrombocytopenia purpura (<jats:styled-content style="fixed-case">ITP</jats:styled-content>) presents a clinical challenge. Second‐line treatment options are variable without a precise protocol. We present 46 severe <jats:styled-content style="fixed-case">ITP</jats:styled-content> patients treated with mycophenolate mofetil (<jats:styled-content style="fixed-case">MMF</jats:styled-content>), retrospectively identified from three London teaching hospitals. Data was collected on patient demographics, co‐morbidities and previous treatment strategies. Our key interest was whether there was a sustained response in platelet count to <jats:styled-content style="fixed-case">MMF</jats:styled-content>. Patients included 27 males and 19 females whose ages ranged from 19 to 93 years old (median 52·5 years). Twenty‐nine had primary <jats:styled-content style="fixed-case">ITP</jats:styled-content> and 17 had secondary <jats:styled-content style="fixed-case">ITP</jats:styled-content>, a third of whom had viral‐associated disease. The standard dose of <jats:styled-content style="fixed-case">MMF</jats:styled-content> was 1 g/day. Twenty‐four patients (52%) responded with 15 (33%) achieving a complete response. No active viral‐associated <jats:styled-content style="fixed-case">ITP</jats:styled-content> patients demonstrated a response to <jats:styled-content style="fixed-case">MMF</jats:styled-content>, although numbers were small (<jats:italic>n</jats:italic> = 4). We were not able to demonstrate a difference between responders and non‐responders based on gender, age, previous therapies or time since diagnosis of <jats:styled-content style="fixed-case">ITP<
Escobedo-Cousin M, Jackson N, Laza-Briviesca R, et al., 2015, Natural Killer Cells Improve Hematopoietic Stem Cell Engraftment by Increasing Stem Cell Clonogenicity In Vitro and in a Humanized Mouse Model, PLOS ONE, Vol: 10, Pages: e0138623-e0138623
Psaila B, Cooper N, 2015, B-cell depletion in immune thrombocytopenia, LANCET, Vol: 385, Pages: 1599-1601, ISSN: 0140-6736
Hui YMT, Pillinger T, Luqmani A, et al., 2015, Haemophagocytic lymphohistiocytosis associated with Mycobacterium tuberculosis infection, Case Reports, Vol: 2015, Pages: bcr2014208220-bcr2014208220, ISSN: 1757-790X
Khoder A, Sarvaria A, Alsuliman A, et al., 2014, Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD, Blood, Vol: 124, Pages: 2034-2045, ISSN: 0006-4971
A subset of regulatory B cells (Bregs) in mice negatively regulate T-cell immune responses through the secretion of regulatory cytokines such as IL-10 and direct cell-cell contact and have been linked to experimental models of autoimmunity, inflammation, and cancer. However, the regulatory function of Bregs in human disease is much less clear. Here we demonstrate that B cells with immunoregulatory properties are enriched within both the CD19+IgM+CD27+ memory and CD19+CD24hiCD38hi transitional B-cell subsets in healthy human donors. Both subsets suppressed the proliferation and interferon-γ production of CD3/CD28-stimulated autologous CD4+ T cells in a dose-dependent manner, and both relied on IL-10 secretion as well as cell-cell contact, likely mediated through CD80 and CD86, to support their full suppressive function. Moreover, after allogeneic stem cell transplantation, Bregs from patients with chronic graft-versus-host disease (cGVHD) were less frequent and less likely to produce IL-10 than were Bregs from healthy donors and patients without cGVHD. These findings suggest that Bregs may be involved in the pathogenesis of cGVHD and support future investigation of regulatory B cell–based therapy in the treatment of this disease.
Onubogu IK, Cooper N, Naresh K, et al., 2013, Alternative Methods Of Thrombocytopenia: Patients With ITP Have Increased Megakaryocyte/T Cell Interactions In The Bone Marrow and Higher Serum TRAIL Levels, 55th Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, ISSN: 0006-4971
de Lavallade H, Khoder A, Hart M, et al., 2013, Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling, BLOOD, Vol: 122, Pages: 227-238, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 83
Rodeghiero F, Michel M, Gernsheimer T, et al., 2013, Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group, BLOOD, Vol: 121, Pages: 2596-2606, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 144
Godfrey CL, Terrinoni I, Laffan M, et al., 2012, Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP), 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 5
Robak T, Windyga J, Trelinski J, et al., 2012, Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia, BLOOD, Vol: 120, Pages: 3670-3676, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 43
Ali S, Sergeant R, O'Brien SG, et al., 2012, Dasatinib may overcome the negative prognostic impact of <i>KIR2DS1</i> in newly diagnosed patients with chronic myeloid leukemia, BLOOD, Vol: 120, Pages: 697-698, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 21
Patel VL, Mahevas M, Lee SY, et al., 2012, Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia, BLOOD, Vol: 119, Pages: 5989-5995, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 229
Manson AL, Zaheri S, Kelleher P, et al., 2012, Management of granulomatous common variable immunodeficiency diagnosed in pregnancy: a case report, JOURNAL OF PERINATOLOGY, Vol: 32, Pages: 387-389, ISSN: 0743-8346
- Author Web Link
- Cite
- Citations: 6
Cooper N, Rao K, Goulden N, et al., 2012, Alpha interferon augments the graft-versus-leukaemia effect of second stem cell transplants and donor lymphocyte infusions in high-risk paediatric leukaemias., Br J Haematol, Vol: 156, Pages: 550-552
Marin D, Gabriel IH, Ahmad S, et al., 2012, KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib, LEUKEMIA, Vol: 26, Pages: 296-302, ISSN: 0887-6924
- Author Web Link
- Cite
- Citations: 41
O'Donovan EM, Rezvani K, Sargent J, et al., 2011, Thrombopoietic Agonists Show Efficacy in ITP Related to Allogeneic Stem Cell Transplantation, 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, Publisher: AMER SOC HEMATOLOGY, Pages: 1415-1416, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 1
Cooper N, Hart D, Bates I, et al., 2011, The importance of developing world haematology, British Journal of Haematology, Vol: 154, Pages: 667-667, ISSN: 0007-1048
Garland P, de Lavallade H, Sekine T, et al., 2011, Humoral and Cellular Immunity to Primary H1N1 Infection in Patients with Hematologic Malignancies following Stem Cell Transplantation, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, Vol: 17, Pages: 632-639, ISSN: 1083-8791
- Author Web Link
- Cite
- Citations: 11
Patel A, Cooper N, Laffan MA, 2011, Safety of Recombinant Activated Factor VII in Randomized Clinical Trials., The New England Journal of Medicine, Vol: 364
de Lavallade H, Garland P, Sekine T, et al., 2011, Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host., Haematologica, Vol: 96, Pages: 307-314
BACKGROUND: In 2009 the declaration by the World Health Organization of a global pandemic of influenza-H1N1 virus led to a vaccination campaign to ensure protection for immunocompromised patients. The goal of this study was to determine the efficacy of the 2009 H1N1 vaccine in patients with hematologic malignancies. DESIGN AND METHODS: We evaluated humoral and cellular immune responses to 2009 H1N1 vaccine in 97 adults with hematologic malignancies and compared these responses with those in 25 adult controls. Patients received two injections of vaccine 21 days apart and the controls received one dose. Antibody titers were measured using a hemagglutination-inhibition assay on days 0, 21 and 49 after injection of the first dose. Cellular immune responses to H1N1 were determined on days 0 and 49. RESULTS: By day 21 post-vaccination, protective antibody titers of 1:32 or more were seen in 100% of controls compared to 39% of patients with B-cell malignancies (P<0.001), 46% of allogeneic stem cell transplant recipients (P<0.001) and 85% of patients with chronic myeloid leukemia (P=0.086). After a second dose, seroprotection rates increased to 68%, (P=0.008), 73%, (P=0.031), and 95% (P=0.5) in patients with B-cell malignancies, after allogeneic stem cell transplantation and with chronic myeloid leukemia, respectively. On the other hand, T-cell responses to H1N1 vaccine were not significantly different between patients and controls. CONCLUSIONS: These data demonstrate the efficacy of H1N1 vaccine in most patients with hematologic malignancies and support the recommendation for the administration of two doses of vaccine in immunocompromised patients. These results may contribute towards the development of evidence-based guidelines for influenza vaccination in such patients in the future.
Patel VL, Mahevas M, Stasi R, et al., 2010, Long Term Outcome Following B Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP), Pages: 38-39, ISSN: 0006-4971
Patel VB, Mahevas M, Stasi R, et al., 2010, Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP), 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, Pages: 38-39, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 6
Gabriel IH, Sergeant R, Szydlo R, et al., 2010, Interaction between <i>KIR3DS1</i> and <i>HLA</i>-<i>Bw4</i> predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma, BLOOD, Vol: 116, Pages: 2033-2039, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 36
Cook L, Cooper N, 2010, Eltrombopag - a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations, DRUG DESIGN DEVELOPMENT AND THERAPY, Vol: 4, Pages: 139-145, ISSN: 1177-8881
- Author Web Link
- Cite
- Citations: 5
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.